Lumateperone rises to the top in this analysis, but there’s a big caveat
STUDY: Cutler AJ et al, Adv Ther 2026
STUDY TYPE: Network meta-analysis
FUNDING: Johnson & Johnson
Background
The FDA has approved five antipsychotics for adjunctive use in depression: aripiprazole, brexpiprazole, cariprazine, quetiapine XR, and lumateperone (olanzapine is approved only with fluoxetine; risperidone is effective but not approved).
Meta-analyses usually favor aripiprazole, but those did not include lumateperone (Caplyta). This is the first to do so (and is sponsored by the manufacturer).
The Study
- Ten registrational randomized controlled trials (446–819 patients each) comparing five atypical antipsychotics plus an antidepressant versus placebo plus an antidepressant.
- Agents included aripiprazole, brexpiprazole, cariprazine, lumateperone 42 mg/day, and quetiapine at two doses each; all trials lasted 6 weeks.
- Primary outcome: change from baseline on the Depression scale (MADRS). Secondary outcomes included clinical response, remission, global severity (CGI-S), weight change, akathisia, and somnolence.
Results
All five agents reduced depression scores more than placebo. Lumateperone had the largest effect on the MADRS (mean difference vs. placebo: −4.70 points), compared to the next best, brexpiprazole 2 mg (−3.20). In direct pairwise comparisons, lumateperone outperformed or trended better than every other agent across all four efficacy outcomes.
The statistical ranking tool (SUCRA) placed lumateperone first across all efficacy measures: depression severity (97.4%), response (91.9%), remission (90.4%), and global severity (98.9%).
Lumateperone was also the least likely to cause weight gain, but short-term side effects caused high drop-out rates on this antipsychotic in an analysis of schizophrenia trials, such as sedation and dizziness.
However, there is a major limitation with this analysis.
Limitations
The lumateperone trials enrolled patients with lower levels of treatment resistance (1-2 failures), while aripiprazole and brexpiprazole trials required failure of 1 to 3 prior antidepressants. Less resistance means higher response rates.
There are reasons to favor the lower-cost aripiprazole. It has
- The most trials in depression
- The most trials with true treatment resistance (at least 2 failed antidepressants)
- The most support in the elderly
- An effect size close to lumateperone in more difficult-to-treat patients
Brexpiprazole’s effect size is in a similar range, but it failed to prevent depression in its two maintenance trials. Aripiprazole, in contrast, has some long-term data supporting it, but not in a placebo-controlled test, only against an active comparator (bupropion augmentation).
Other limitations:
- No head-to-head trials exist, so all comparisons are indirect.
- Each treatment node was based on only one or two trials.
- The analysis was funded by Johnson & Johnson, the maker of lumateperone, and several authors are company employees.
- Short trial duration (6 weeks) limits conclusions about long-term outcomes, and many antipsychotics fail in maintenance phase of major depression (olanzapine and possibly quetiapine are exceptions).
Practice Implications
- Lumateperone stands out for efficacy, but the differences are minor and the patients it was tested in were easier to treat. It is also expensive.
- Aripiprazole is a good first-line option, with lumateperone second.
- Quetiapine also wins for its benefits in anxiety and sleep, but this one is hard to tolerate.
—Chris Aiken, MD
Director, Psych Partners
Editor in Chief, Carlat Psychiatry Report
What’s Your Take? Share in Comments
